Billions of People Lack Timely Access to Diagnostics. A Space-Tested Technology Backed by NASA and the NIH Aims to Fix That, and is Nearing FDA Registration

NASA had a problem. It needed a way to ensure its astronauts were staying healthy while in space, where there are no doctors or labs available to do bloodwork. 

Down here on Earth, more than half the global population face the same issue. The World Health Organization estimates 4.5 billion people lack timely access to diagnostics testing, and it often takes weeks for physicians to interpret results. That means delays in care for the more than 194 million U.S. adults managing chronic conditions. 

The potential solution to both of these issues? rHEALTH’s at-home diagnostics tools that deliver lab-quality results in up to 20 minutes from a self-collected blood sample. 

This patent-protected technology has been tested on the International Space Station, and is now being adapted for point-of-care settings and eventually private homes. 

With the technology and potential to run more than 100 tests in a single device and backing from NASA and the National Institutes of Health, rHEALTH aims to disrupt the $323 billion blood diagnostics market. 

FDA registration is targeted within approximately 12 months. 

Backed by Science

The rHEALTH ONE was tested aboard the International Space Station by astronaut Samantha Cristoforetti in some of the most extreme conditions. 

The technology’s results have been published in top, peer-reviewed science journals and was specifically picked by NASA following a review of competing diagnostic platforms for space use. 

The system was also founded by a Harvard/MIT-trained physician who invested $2 million of his personal money into the company. There are 17 U.S. patents covering its device architecture, diagnostic algorithms, and miniaturized components. 

Strategic partnerships have been launched with Mayo Clinic, Boston Children’s Hospital, Massachusetts General Hospital, NASA, NIH, and AstraZeneca. rHEALTH has also been awarded more than $20 million in non-dilutive funding based on its technical feasibility and merit. 

Capitalizing on Global Health Trends  

rHEALTH is operating in multi-billion dollar markets:

• A $16.2 billion obtainable market focused on hematology diagnostics 
• A $224 billion serviceable market focused on lab, point-of-care, and home testing 
• The $323 billion global diagnostics and patient monitoring market 

With more than 500 million blood tests performed each year in the U.S. alone, there’s a growing need for accessible diagnostics tools and decentralized care. 

rHEALTH plans on utilizing complementary revenue streams to support upfront and recurring revenue: device sales, test cartridges, and software subscriptions.  

Own a Piece Of Space-Tested Technology 

The World Health Organization has historically called for increased access to diagnostic tools. 

Most tools, however, only test for one condition. That means multiple tests, blood draws, and appointments that billions of people around the world don’t have access to. Even then, labs and physicians are often required to process and interpret the results. 

rHealth is one platform with the potential to run more than 100 tests and is built to keep expanding, like an app store for diagnostics. 
Complete information is available at  https://www.startengine.com/offering/rhealth.

This Reg CF offering is made available throughStartEngine Primary, LLC, member FINRA/SIPC. This investment is speculative,illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

Benzinga is compensated for publicizing this content. Please read 17b disclosures here.